Latest News

Proposal to fund treatment earlier for relapsing remitting multiple sclerosis

May 30, 2022 | Advocacy, Life with MS, Treatments

We are excited to announce that following 7 years of relentless advocacy by Multiple Sclerosis NZ (MSNZ), Pharmac have opened the consultation process to increase earlier access to treatments for relapsing remitting MS. We now need YOUR HELP to get […]


Preclinical data support remyelinating potential of ABX-002

May 24, 2022 | Research

ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented […]


Is lack of access to pools a barrier to low-impact aquatic exercise?

May 24, 2022 | Uncategorised

Aquatic exercise is used less often by people with multiple sclerosis (MS) than land-based exercise, but it’s generally well liked by those who use it, a patient survey found. A lack of pool access and associated expenses remain significant barriers to aquatic […]


More funded medicines for New Zealanders?

May 23, 2022 | Media, Treatments

Media article: 19 May 2022 Pharmac welcomes the $191 million increase to its pharmaceutical budget over the next two years. It is already working its way through the medicines options for investment (OFI) list, looking at what agreements it can […]


My aHSCT story – Lucy Kerly

May 23, 2022 | Advocacy, Life with MS, My Story, Treatments

Lucy Kerly had aHSCT on the NHS at Hammersmith Hospital in London at the beginning of 2022. Both she and her husband live with MS – Steve was diagnosed with relapsing MS in 2003 when he was 29 and travelled […]